Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
STU:2TZ's Quick Ratio is ranked better than 59.72% of 998
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs STU:2TZ: 1.78
Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Tianjin Pharmaceutical Da Ren Tang Group Quick Ratio Related Terms
Tianjin Pharmaceutical Da Ren Tang Group Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin Pharmaceutical Da Ren Tang Group Quick Ratio Chart
Tianjin Pharmaceutical Da Ren Tang Group Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianjin Pharmaceutical Da Ren Tang Group Quick Ratio vs Drug Manufacturers Industry
Tianjin Pharmaceutical Da Ren Tang Group Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) has a Quick Ratio of 1.78 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. This is near median its historical median of 1.71. Over the past decade, Tianjin Pharmaceutical Da Ren Tang Group's Quick Ratio has ranged from 1.26 to 2.33. According to the industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #402 out of 998 companies in the Drug Manufacturers industry, placing it in the top 40.3%.
Is Tianjin Pharmaceutical Da Ren Tang Group's Quick Ratio too high?
Tianjin Pharmaceutical Da Ren Tang Group's current Quick Ratio of 1.78 is near median its 10-year median of 1.71. Over the past 10 years, this metric has ranged from a low of 1.26 to a high of 2.33. The Drug Manufacturers industry median Quick Ratio is 1.45. Tianjin Pharmaceutical Da Ren Tang Group's value of 1.78 is 22.8% above this industry median. Based on the distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #402 out of 998 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Tianjin Pharmaceutical Da Ren Tang Group has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin Pharmaceutical Da Ren Tang Group's Quick Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #402 out of 998 companies for Quick Ratio. This puts Tianjin Pharmaceutical Da Ren Tang Group in the upper half of its industry. The industry median Quick Ratio is 1.45. Tianjin Pharmaceutical Da Ren Tang Group's value of 1.78 is 22.8% above this benchmark. Historically, Tianjin Pharmaceutical Da Ren Tang Group's own Quick Ratio has ranged from 1.26 to 2.33 over the past decade. While the company's 10-year median is 1.71 vs. the industry median of 1.45, Tianjin Pharmaceutical Da Ren Tang Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tianjin Pharmaceutical Da Ren Tang Group's current Quick Ratio of 1.78 is 22.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tianjin Pharmaceutical Da Ren Tang Group's current Quick Ratio is 1.78, which is near median its own 10-year median of 1.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin Pharmaceutical Da Ren Tang Group stock overvalued right now?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.64, compared to a current price of €2.44 — trading 48.8% above its estimated fair value. The current Quick Ratio is 1.78, which is near median its 10-year median of 1.71 and 22.8% above the Drug Manufacturers industry median of 1.45. Tianjin Pharmaceutical Da Ren Tang Group's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ), the current Quick Ratio is 1.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) Overvalued in 2026?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group stock appears to be overvalued.
The current stock price of €2.44 is trading 48.8% above its estimated GF Value™ of €1.64.
GuruFocus considers Tianjin Pharmaceutical Da Ren Tang Group to be Significantly Overvalued.
Key valuation signals for STU:2TZ:
Quick Ratio: 1.78 (near median its 10-year median of 1.71)
GF Value™: €1.64 vs. price of €2.44 (48.8% above fair value)
Industry Position: 22.8% above the Drug Manufacturers median (#402 of 998)
No single metric tells the full story. See the STU:2TZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianjin Pharmaceutical Da Ren Tang Group Business Description
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company is engaged in the production and sale of traditional Chinese medicine, Western medicine, healthcare products, and investment holding. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese medicine.
72GF Score
Get the complete analysis for STU:2TZ
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2TZ has been successfully added to your 
